ASH 2025: Optimizing MM Care: Key Trials and Consensus Updates on Targeted, Immune-Based, and Risk-Adapted Approaches
Explore recent pivotal trials and consensus updates in multiple myeloma, including MajesTEC-3, COBRA, and the first IMS–IMWG high-risk definition. This article highlights immunotherapy advances, proteasome...
